Cinaciguat acts specifically on oxidized/haem-free soluble guanylyl cyclase by binding to the enzyme's haem pocket and mimicking the nitric-oxide-bound haem group. It is in clinical development for the treatment of acute decompensated heart failure. Cinaciguat had been in phase II clinical trials. However, trials were terminated early because of an excess of hypotension in the cinaciguat arms and subsequent slow enrolment.

Etriciguat is a novel potent, selective, orally available soluble guanylate cyclase (sGC) stimulator.

Nebidrazine (FLA-136) is a selective agonist at central alpha-adrenoreceptors mediating changes in the turnover of noradrenaline. Nebidrazine is a sedative agent.

Darsidomine sydnonimine derivative, which serves as NO donor. Administration of darsidomine causes selective dilation of the coronary artery. The drug has an anti-ischemic action without inducing tolerance on long-term administration.

Cyheptropine is a tropine ester of dibenzo[a,d]cycloheptadiene-5-carboxylic acid, developed as an antiarrhythmic agent.

Burodiline is ester of alkoxybenzoic acid with spasmolytic, local anesthetic, and hypotensive properties

Quinuclium Bromide Anhydrous is quinuclidinium derivative with potential analgesic activity. In preclinical studies, Quinuclium possessed significant chronic antihypertensive activity in mecamylamine- and renal-hypertensive dogs. Quinuclium was approximately 4 times more potent than guanethidine in the former model and 3 times as potent in the latter. Quinuclium reduced orthostatic blood pressure responses in unanesthetized rabbits but was approximately 10 times less potent than guanethidine. Quinuclium did not affect cardiac output, heart rate or stroke volume in anesthetized open-chest dogs and moderately increased mean blood pressure and total peripheral resistance. It produced diuresis and saluresis in anesthetized dogs but did not influence water or electrolyte urinary excretion in conscious rats. Quinuclium was more effective than guanethidine in blocking adrenergic neurons and depleting heart norepinephrine levels in experimental animals.

There is no much information related to the biological properties of ftaxilide. It is known, that it’s not intended for therapeutic use, but has the antibacterial properties and used as antiseptic.

Papaveroline was developed in Italy. It was shown that this compound produced a dose-related inhibition of the aggregation of platelets. This compound is also studied in mental disorders caused by a deficit of non-focalized cerebral circulation. However, information about the further development of papaveroline is not available.

Micinicate, a vasodilator was developed as a spasmolytic agent. Information about the current use of this compound is not available.